A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Sarilumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Sponsors Sanofi
- 05 Aug 2019 Planned End Date changed from 1 Jan 2022 to 1 Nov 2023.
- 05 Aug 2019 Planned primary completion date changed from 1 Jul 2021 to 1 May 2023.
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.